Briefly on our new product guidance categories in 2023. As we have turned the corner to sustainable GAAP profitability and with 8 marketed products, we have aligned the product guidance categories with our framework for growth. First, we now combine our enzyme products, including VIMIZIM, NAGLAZYME, BRINEURA, PALYNZIQ, and ALDURAZYME and exclude KUVAN. Second, we will provide individual product guidance for both VOXZOGO and ROCTAVIAN since they represent our new larger market opportunities and significant growth drivers. Going forward, we will still provide actual results for individual product revenues as listed on the first page of our press release issued today and we will continue to comment on the key commercial drivers at the brand level as appropriate.